Indeed, two independently generated tumor cell models of acquired lapatinib resistance have identified BCL2 overexpression as a component of the resistant phenotype26,39 and suggest that BCL2 upregulation via the adaptive response (de novo resistance) could be maintained by stable, inherited alterations that lead to long-term acquired resistance. Here, BCL2 is linked to neoplasm.